Therefore, in a subset of HNSCC, SHP099 blocks both MEK/ERK signaling and PI3K signaling, converging on mTORC1, likely explaining the potent anticancer activity of SHP2 inhibition. The gene discussed is MAP2K7; the disease is head and neck squamous cell carcinoma.